Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEURAMATE vs KEPPRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Short-term treatment of insomnia,Preoperative sedation,Emergency management of acute seizure episodes,Induction of coma for intracranial pressure reduction
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
250 mg orally three times daily; maximum 1000 mg/day.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
6-8 hours (normal renal function); prolonged to 12-20 hours in moderate renal impairment.
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Primarily hepatic via hydroxylation and conjugation; involves CYP450 enzymes (CYP2C9, CYP2C19); active metabolites; excreted renally.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Primarily renal (90% unchanged) with 10% biliary/fecal.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
<10% (albumin).
<10% bound to plasma proteins (albumin).
0.8 L/kg (suggests distribution into total body water).
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
Oral: 98%; IM: 90%.
Oral: 100% (immediate-release formulation); IV: 100%.
GFR 30-59 m L/min: 250 mg twice daily; GFR 15-29 m L/min: 250 mg once daily; GFR <15 m L/min: 250 mg every other day.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
For children 2-12 years: 10 mg/kg/day in 3 divided doses, increasing over 2 weeks to 30 mg/kg/day; maximum 60 mg/kg/day.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
Initiate at 125 mg twice daily; titrate slowly; monitor renal function and adjust based on creatinine clearance.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
Risk of respiratory depression, especially when administered intravenously; risk of dependence and withdrawal; not for use in patients with porphyria.
None
Respiratory depression; hypotension; paradoxical excitation; risk of abuse and dependence; withdrawal seizures upon abrupt discontinuation; use with caution in hepatic/renal impairment; elderly patients; pregnancy category D.
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
History of porphyria; severe respiratory insufficiency; hypersensitivity to barbiturates; pregnancy (especially third trimester); breastfeeding; myasthenia gravis; acute or chronic pain.
Hypersensitivity to levetiracetam or any of its components
Food does not significantly alter absorption. Avoid grapefruit juice as it may inhibit metabolism and increase toxicity. Maintain adequate hydration to reduce risk of nephrolithiasis.
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
NEURAMATE is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 4-fold increased risk of major congenital malformations, particularly neural tube defects (spina bifida, anencephaly), orofacial clefts, and cardiovascular anomalies. Second and third trimester exposure is linked to decreased IQ scores, autism spectrum disorders, and neurodevelopmental delays in offspring. Neonatal withdrawal syndrome (hyperirritability, feeding difficulties, respiratory distress) may occur with third trimester exposure.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
NEURAMATE is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.8–1.0. Infant serum levels can reach 10–20% of maternal therapeutic concentrations. Breastfeeding is not recommended due to risk of infant sedation, poor suckling, and potential long-term neurodevelopmental effects. If breastfeeding is essential, monitor infant for excessive drowsiness, feeding problems, and weight gain.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
Pregnancy reduces NEURAMATE serum concentrations by 50–70% due to increased volume of distribution, enhanced hepatic clearance (CYP2C9 induction by estrogens), and decreased albumin binding. Total daily dose may need to be increased by 30–50% above prepregnancy baseline to maintain therapeutic trough levels (50–100 mcg/m L). Administer in 3–4 divided doses to minimize peak-to-trough fluctuations. Monitor serum levels every 2–4 weeks and adjust dose accordingly. Postpartum, reduce dose to prepregnancy level within 1–2 weeks to avoid toxicity.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
NEURAMATE (felbamate) is a second-line antiepileptic due to risk of aplastic anemia and hepatotoxicity. Obtain informed consent, baseline CBC and LFTs, and monitor closely. Titrate slowly to minimize sedation. Not first-line for any indication.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
Report any signs of infection, bruising, or bleeding immediately.,Report jaundice, abdominal pain, or dark urine promptly.,Do not stop abruptly; taper under medical supervision to avoid withdrawal seizures.,May cause dizziness, ataxia, or sedation; avoid driving until effects known.,Use effective contraception; felbamate reduces oral contraceptive efficacy.
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEURAMATE vs KEPPRA, answered by our medical review team.
NEURAMATE is a Antiepileptic that works by NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.. KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEURAMATE and KEPPRA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEURAMATE is: 250 mg orally three times daily; maximum 1000 mg/day.. The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEURAMATE and KEPPRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEURAMATE is classified as Category C. NEURAMATE is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 4-fold increased risk of major congenital malformations, particularly neural tube. KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.